Rheumatoid arthritis

55 trials 20 recruiting MedDRA PT
55 Registered trials
20 Recruiting
40 Unique sponsors
31 Unique IMPs
40 Commercial trials
Drug classes (ATC)
— ATC code not specified 33
N Neurology/Psychiatry (ATC N) 2
L Oncology (ATC L) 19
S Ophthalmology/ENT (ATC S) 1
H Endocrinology (ATC H) 2
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 11 substances
JAK inhibitor 3 substances
Monoclonal antibody (human) 2 substances
Monoclonal antibody (immune) 2 substances
Monoclonal antibody (immune, humanized) 2 substances
Monoclonal antibody 2 substances
Receptor fusion protein 2 substances
Monoclonal antibody (chimeric) 2 substances
Monoclonal antibody (humanized) 1 substance
FcRn antagonist 1 substance
Antimetabolite 1 substance
EGFR inhibitor 1 substance
Corticosteroid 1 substance
Phase III: 7 Phase II/III: 2 Phase II: 12 Phase I/II: 3 Phase III/IV: 1 Phase IV: 9 Phase I: 6 Phase I (Other): 13 Phase I (First in Human): 1 Other: 1 Other: 1

Filter these 55 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 55 trials

Phase III

7 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ADALIMUMAB; UPADACITINIB
    2022-501017-31-00 17 countries 2016 n=489
    Ended
  • Alfasigma S.p.A. Commercial
    FILGOTINIB
    2024-513919-27-00 3 countries 2017 n=254
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    ABATACEPT; ADALIMUMAB
    2023-506450-20-00 6 countries 2021 n=141
    Ended
  • Celltrion Inc. Commercial
    INFLIXIMAB
    2024-510945-32-00 1 country 2024 n=189
    Ended
  • Dr Reddy's Laboratories Limited Commercial
    TOCILIZUMAB
    2022-501361-44-00 7 countries n=357
    Not authorised
  • Dr Reddy's Laboratories Limited Commercial
    ABATACEPT; METHOTREXATE
    2023-506664-14-00 8 countries 2024 n=415
    Ended
  • Mabxience Research S.L. Commercial
    ETANERCEPT
    2024-510826-16-00 4 countries 2025 n=548
    Ended

Phase II/III

2 trials
  • Kyverna Therapeutics Inc. Commercial
    KYV-101
    2024-511198-31-00 1 country 2026 n=30 Orphan
    Recruiting
  • Aarhus University Hospital Academic
    IMP not specified
    2022-500922-13-00 1 country 2023 n=40
    Ended

Phase II

12 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    LUTIKIZUMAB; RAVAGALIMAB
    2025-520721-21-00 6 countries 2025 n=108
    Recruiting
  • Anaptysbio Inc. Commercial
    ROSNILIMAB
    2023-504564-42-00 9 countries 2024 n=200
    Ended
  • Artiva Biotherapeutics Inc. Commercial
    ALLOGENEIC UMBILICAL CORD BLOOD-DERIVED NATURAL KILLER CELLS, EX VIVO EXPANDED
    2025-520461-41-00 8 countries 2025 n=17
    Recruiting
  • Elevara Medicines Limited Commercial
    ELV001
    2025-524005-32-00 6 countries n=95
    Pending
  • F. Hoffmann-La Roche AG Commercial
    RO7790121
    2025-523579-47-00 7 countries n=46
    Pending
  • Janssen - Cilag International Commercial
    CERTOLIZUMAB PEGOL; NIPOCALIMAB
    2023-504045-31-00 3 countries 2024 n=55
    Ended
  • Novartis Pharma AG Commercial
    IANALUMAB
    2023-508996-35-00 7 countries 2024 n=69
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    SAR441566
    2023-503910-60-00 6 countries 2024 n=194
    Ended
  • Solfarcos Solucoes Farmaceuticas E Cosmeticas Lda. Commercial
    METHOTREXATE
    2023-510258-17-00 1 country 2024 n=40
    Ended
  • Spyre Therapeutics Inc. Commercial
    SPY072
    2025-521791-63-00 4 countries 2025 n=236
    Ended
  • Universitaetsklinikum Heidelberg AöR Academic
    IMP not specified
    2024-514026-23-00 1 country 2023 n=20
    Ended
  • Anaptysbio Inc. Academic
    ROSNILIMAB
    2023-504564-42-00 9 countries 2024 n=200
    Ended

Phase I/II

3 trials
  • Charite Universitaetsmedizin Berlin KöR Academic
    ABATACEPT; DARATUMUMAB
    2024-511536-27-00 1 country 2025 n=23
    Recruiting
  • Charite Universitaetsmedizin Berlin KöR Academic
    KYV-101; RITUXIMAB
    2024-514955-13-00 1 country 2024 n=16
    Recruiting
  • Fraunhofer Institute For Translational Medicine And Pharmacology ITMP Academic
    CIZUTAMIG
    2025-522857-20-00 1 country 2026 n=12
    Recruiting

Phase III/IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ADALIMUMAB; UPADACITINIB
    2022-502578-18-00 11 countries 2023 n=148
    Ended

Phase IV

9 trials
  • Cliniques Universitaires Saint-Luc Academic
    SARILUMAB
    2024-514201-61-00 1 country 2019 n=30
    Recruiting
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Academic
    TOFACITINIB
    2024-517865-17-01 1 country 2024 n=84
    Recruiting
  • Karolinska Institutet Academic
    CERTOLIZUMAB PEGOL; TOCILIZUMAB; TRIAMCINOLONE HEXACETONIDE
    2024-516723-14-00 4 countries n=705
    Pending
  • Karolinska University Hospital Academic
    PREDNISOLONE
    2024-518775-54-00 1 country 2021 n=166
    Recruiting
  • Queen Mary University Of London Academic
    ETANERCEPT; SARILUMAB
    2022-502021-18-00 5 countries 2023 n=182
    Recruiting
  • Queen Mary University Of London Academic
    ABATACEPT
    2024-511470-79-00 5 countries 2025 n=182
    Recruiting
  • Region Skane Academic
    RESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E; RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A, RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP B, STABILIZED PREFUSION F PROTEIN 847B
    2024-518191-31-00 1 country n=180
    Pending
  • UZ Leuven Academic
    RITUXIMAB
    2023-506638-59-01 1 country 2024 n=134
    Recruiting
  • UZ Leuven Academic
    ETANERCEPT
    2023-510189-28-00 1 country 2018 n=442
    Ended

Phase I

6 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2023-509574-34-00 1 country 2024 n=29
    Ended
  • AstraZeneca AB Commercial
    IMP not specified
    2024-519015-34-00 4 countries 2025 n=32
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2024-517681-41-00 6 countries 2025 n=93
    Recruiting
  • Lifordi Immunotherapeutics Inc. Commercial
    IMP not specified
    2025-523409-13-00 1 country n=40
    Pending
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2024-511297-73-00 1 country 2024 n=96
    Ended
  • Neurocrine Biosciences Inc. Commercial
    IMP not specified
    2025-525113-22-00 2 countries n=15
    Pending

Phase I (Other)

13 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2025-522273-10-00 3 countries 2026 n=15
    Recruiting
  • Celgene Corp. Commercial
    IMP not specified
    2023-503823-24-01 5 countries 2024 n=126
    Halted
  • Cullinan Therapeutics Inc. Commercial
    IMP not specified
    2024-519114-31-00 3 countries 2025 n=46
    Recruiting
  • Gilead Sciences Inc. Commercial
    IMP not specified
    2024-516520-34-00 3 countries 2025 n=39
    Recruiting
  • IGM Biosciences Inc. Commercial
    IMP not specified
    2023-505127-31-00 1 country 2024 n=9
    Ended
  • Ilab Co. Ltd. Commercial
    IMP not specified
    2023-510247-38-00 1 country 2024 n=35
    Ended
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2024-516548-25-00 1 country 2025 n=40
    Ended
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2024-518104-47-00 1 country 2024 n=48
    Ended
  • Novartis Pharma AG Commercial
    IMP not specified
    2024-520196-27-00 7 countries 2025 n=40
    Recruiting
  • Pfizer Inc. Commercial
    IMP not specified
    2023-505603-23-00 1 country 2024 n=12
    Ended
  • Philogen S.p.A. Commercial
    IMP not specified
    2024-517896-19-00 1 country 2025 n=42
    Recruiting
  • SciRhom GmbH Commercial
    IMP not specified
    2025-523678-17-00 1 country n=12
    Pending
  • Pfizer Inc. Academic
    RITLECITINIB TOSILATE
    2022-502872-22-00 1 country 2023 n=12
    Ended

Phase I (First in Human)

1 trial
  • Quell Therapeutics Limited Commercial
    QEL-005
    2025-523971-46-00 2 countries n=8
    Pending

Other

1 trial
  • Mabxience Research S.L. Commercial
    IMP not specified
    2023-507877-17-00 1 country 2024 n=132
    Ended

Other

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2023-508030-33-00 1 country 2024 n=13
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 3 Phase I, Phase I (Other) 2
Merck Sharp & Dohme LLC Commercial 3 Phase I, Phase I (Other) 0
AbbVie Deutschland GmbH & Co. KG Commercial 3 Phase III/IV, Phase II, Phase III 1
Bristol-Myers Squibb Services Unlimited Company Commercial 2 Phase I, Phase III 1
Mabxience Research S.L. Commercial 2 Other, Phase III 0
Novartis Pharma AG Commercial 2 Phase I (Other), Phase II 2
Pfizer Inc. Commercial 2 Phase I (Other) 0
Anaptysbio Inc. Commercial 2 Phase II 0
Sanofi-Aventis Recherche & Developpement Commercial 2 Phase II, Other 0
Dr Reddy's Laboratories Limited Commercial 2 Phase III 0
Queen Mary University Of London Academic 2 Phase IV 2
UZ Leuven Academic 2 Phase IV 1
Charite Universitaetsmedizin Berlin KöR Academic 2 Phase I/II 2
Lifordi Immunotherapeutics Inc. Commercial 1 Phase I 0
Neurocrine Biosciences Inc. Commercial 1 Phase I 0
Kyverna Therapeutics Inc. Commercial 1 Phase II/III 1
Celgene Corp. Commercial 1 Phase I (Other) 0
Cullinan Therapeutics Inc. Commercial 1 Phase I (Other) 1
Gilead Sciences Inc. Commercial 1 Phase I (Other) 1
IGM Biosciences Inc. Commercial 1 Phase I (Other) 0
New trials by year
2019
1
2021
2
2023
5
2024
20
2025
13
2026
3
← All indication landscapes